I'm searching for informations on the "time to relapse". I found a little bit of litterature on this topic but it's always on the context of clinical trials. I would like to know if there is some papers on this applyed on the preclinical trials.
Thanks you !
In rodent models, this would classically involve surgical resection of the primary tumor and time to recurrence at the primary site. This assumes that the primary site is observable either grossly, IVIS etc.
I've never heard the "time to relapse" study in preclinical setting (maybe there is, but I've never heard or seen one). Usually time of relapse or recurrence are being studied in clinical setting. As sometimes the process could take years before it really happen, so using animal to measure the time to relapse is probably not doable due to their limited lifetime.
Oh, and I just noticed that you're putting this question under the label Oncology, and I'm happen to deal with cancer too, breast cancer to be more specific. From what I've learned the time to relapse in breast cancer (after surgery, radiation, and/or hormone therapy) could take years, sometimes even 11-12 years, so of course it only possible in clinical settings.
An orthotopic 4T1 primary tumor that is resected at a 1cm diameter primary will relapse within 2 weeks. An orthotopic melanoma primary tumor (B16-BL6) at a sc site will relapse within a week or so of resection. In the case of a primary footpad injection it will not relapse assuming you capture the popliteal LN at resection. SOPs for doing this are readily available.
See studies by Josh Fidler (B16), James Talmadge (B16, 4T1), Suzanne Ostrand-Rosenburg (4T1), Rita Young (3LL), Bob Wiltrout (RENCA).
I wondered myself if there could be studies on the time to relapse on preclinical studies but as I didn't found anything on it, I was almost sure that this couldn't be done in preclinical studies.
Thanks for your hels, I'm gonna look for that in clinical trials !
"I'm gonna look for that in clinical trials" --> What does that mean? Does it means that you won't do some more research about time to relapse on preclinical trial? In case you didn't notice, James stated that in his research group he managed to create a rodent models for time to relapse study.
Int Immunopharmacol. 2014 Sep;22(1):167-75. doi: 10.1016/j.intimp.2014.06.021. Epub 2014 Jun 25.Suicide plus immune gene therapy prevents post-surgical local relapse and increases overall survival in an aggressive mouse melanoma setting. Villaverde MS1, Combe K2, Duchene AG3, Wei MX2, Glikin GC1, Finocchiaro LM4.
Ann Surg Oncol. 2008 Oct;15(10):2954-64. doi: 10.1245/s10434-008-0037-5. Epub 2008 Jul 12. Mechanisms driving local breast cancer recurrence in a model of breast-conserving surgery. Smith MJ1, Culhane AC, Killeen S, Kelly MA, Wang JH, Cotter TG, Redmond HP.
NDRG2 correlated with favorable recurrence-free survival inhibits metastasis of mouse breast cancer cells via attenuation of active TGF-β production. Oh SS, Kim D, Kim DH, Chang HH, Sohn KC, Kim KH, Jung SH, Lee BK, Kim JH, Kim KD. Carcinogenesis. 2012 Oct;33(10):1882-8. doi: 10.1093/carcin/bgs211. Epub 2012 Jun 13.
Inhibition of the Kit ligand/c-Kit axis attenuates metastasis in a mouse model mimicking local breast cancer relapse after radiotherapy. Kuonen F, Laurent J, Secondini C, Lorusso G, Stehle JC, Rausch T, Faes-Van't Hull E, Bieler G, Alghisi GC, Schwendener R, Andrejevic-Blant S, Mirimanoff RO, Rüegg C. Clin Cancer Res. 2012 Aug 15;18(16):4365-74. Epub 2012 Jun 18.
Therapeutic application of injectable thermosensitive hydrogel in preventing local breast cancer recurrence and improving incision wound healing in a mouse model. Lei N, Gong C, Qian Z, Luo F, Wang C, Wang H, Wei Y. Nanoscale. 2012 Sep 21;4(18):5686-93. doi: 10.1039/c2nr30731f. Epub 2012 Aug 9.
TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy. Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M. Cancer Res. 2013 Dec 15;73(24):7211-21. doi: 10.1158/0008-5472.CAN-13-1314. Epub 2013 Oct 23.
Impact of sentinel lymphadenectomy on survival in a murine model of melanoma Robert B. Rebhun Æ Alexander J. F. Lazar Æ Isaiah J. Fidler Æ Jeffrey E. Gershenwald Clin Exp Metastasis (2008) 25:191–199
Mechanisms Driving Local Breast Cancer Recurrence in a Model of Breast-Conserving Surgery Myles J. Smith, MRCSI, PhD,1,2 Aedı´n C. Culhane, PhD,3,4 Shane Killeen, MRCSI, MD,1 Maura A. Kelly, MRCSI,1 Jiang H. Wang, PhD,1 Thomas G. Cotter, D. Phil,2 Henry P. Redmond, MCh, FRCSI1 Annals of Surgical Oncology 15(10):2954–2964
CANCER RESEARCH 64, 2205–2211, March 15, 2004] Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease Erika A. Danna, Pratima Sinha, Mileka Gilbert, Virginia K. Clements, Beth A. Pulaski, and Suzanne Ostrand-Rosenberg
No, that means I'm gonna do some research on time to relapse ALSO on clinical studies because at the begining I was interested in preclinical studies.
- Badges
- Science topic
- Similar topics
- Medicine
- Disease
- Infectious Diseases
- Immunization
- Vaccination